Investor Presentation Q1-Q3 2020

26 Investor presentation First nine months of 2020 Insulin sales remain important with more than 40% share of revenue but with less dependence on the US insulin sales 42% Q3 2015 sales split 28% 30% 57% Q3 2020 sales split IO insulin NAO insulin Other products 30% 13% Novo NordiskⓇ

View entire presentation